Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 15/20 | 0.56 |
| ▸ | MC5R | P33032 | 6/20 | 0.56 |
| ▸ | MC3R | P41968 | 6/20 | 0.56 |
| ▸ | MC1R | Q01726 | 6/20 | 0.56 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.51 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.51 |
| ▸ | TSLP | Q969D9 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615208 | 0.91 | MC4R (0.57) | MC4RMC5RMC3RMC1R | |
| SCHEMBL29615154 | 0.91 | MC4R (0.57) | MC4RMC5RMC3RMC1R | |
| SCHEMBL29615117 | 0.90 | MC4R (0.67) | MC4RMC5RMC3RMC1RSSTR1 | |
| SCHEMBL29615038 | 0.90 | MC4R (0.60) | MC4RMC5RMC3RMC1RSSTR1 | |
| SCHEMBL29615288 | 0.90 | MC4R (0.60) | MC4RMC5RMC3RMC1RSSTR1 | |
| SCHEMBL29615129 | 0.90 | MC4R (0.67) | MC4RMC5RMC3RMC1RSSTR1 | |
| SCHEMBL29615119 | 0.90 | MC4R (0.67) | MC4RMC5RMC3RMC1RSSTR1 | |
| SCHEMBL29615386 | 0.89 | MC4R (0.59) | MC4RMC5RMC3RMC1RSSTR1 | |
| SCHEMBL29615153 | 0.89 | MC4R (0.59) | MC4RMC5RMC3RMC1RSSTR1 | |
| SCHEMBL30787052 | 0.89 | MC4R (0.59) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | claimed |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | disclosed |
| WO-2025106751-A1 | COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12285460-B2 | Pharmaceutical compositions | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12077612-B2 | Peptide compositions | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | MC4R 1/4885MC5R 2/4885MC3R 3/4885 |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | MC4R 268/4885MC5R 314/4885MC3R 143/4885 |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | MC4R 1/4885MC5R 5/4885MC3R 3/4885 |
| US-12285460-B2 | Pharmaceutical compositions | PCTP, SLC27A1, CETP | MC4R 268/4885MC5R 314/4885MC3R 143/4885 |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | MC4R, MC3R, MC5R | MC4R 1/4885MC5R 3/4885MC3R 2/4885 |
| US-12077612-B2 | Peptide compositions | MC4R, MC3R, MC5R | MC4R 1/4885MC5R 3/4885MC3R 2/4885 |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | ARGLU1, FFAR3, ASNS | MC4R 585/4885MC5R 147/4885MC3R 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.